RxDoctor Payments Data

Jennifer Durphy, MD

Neurology · Albany, NYNPI 1295927952

Payments from drug & device makers

$227,172in general payments, 2019–2025

Across 163 payments — averaging $1393.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acorda Therapeutics, Inc$116K
  • Boston Scientific$100K
  • UCB SA$11K
  • Abbott$178
  • Amneal Pharmaceuticals LLC$94
  • MDD US Operations, LLC$81
  • plus $166 from 4 others

What the payments were for

  • Consulting fees$9,2458%
  • Speaking & faculty fees$100,66586%
  • Travel & lodging$4,6084%
  • Food & beverage$2,5422%
  • Education$230%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$227,172 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$62,317
Medicare patients
268
Services billed
899

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate48$254,235
AustedoDeutetrabenazine33$215,578
IngrezzaValbenazine Tosylate18$137,503
GocovriAmantadine Hcl37$132,396
InbrijaLevodopa22$109,881
Droxidopa26$56,266
RytaryCarbidopa/Levodopa14$55,441
Tetrabenazine13$54,703
Carbidopa-LevodopaCarbidopa/Levodopa608$33,187
Carbidopa-Levodopa ErCarbidopa/Levodopa194$17,744
NeuproRotigotine14$14,928
Rasagiline Mesylate37$10,706
Pramipexole ErPramipexole Di-Hcl11$10,409
AmantadineAmantadine Hcl121$9,675
Entacapone27$9,494

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MDD US Operations, LLCGocovri$81$132,39637 claims
Acorda Therapeutics, IncInbrija$115,893$109,88122 claims
Amneal Pharmaceuticals LLCRytary$94$55,44114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,623 neurology providers in New York.

Other neurology in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →